èšåºæ®µéã®å
ç«çæ³äŒæ¥ã§ããINmune Bio, Inc.ã¯ããããã¢ã«ããã€ããŒç
ãéã¢ã«ã³ãŒã«æ§èèªèçãæ²»çããããã«æ£è
ã®èªç¶å
ç«ã·ã¹ãã ãåããã°ã©ã ããããšã«æ³šåããŠããŸããå瀟ã¯ãè¡æ¶²æªæ§è
«çãåºåœ¢è
«çãæ
¢æ§ççãæ²»çããããã®è£œååè£ãéçºããåååããèšç»ã§ããéçºããã°ã©ã ã«ã¯ãåçºé£æ²»æ§åµå·£ããã®å¥³æ§ãšé«ãªã¹ã¯éªšé«ç°åœ¢æçåçŸ€ã®æ£è
ã®æ²»çã«çŠç¹ãåœãŠãINKmuneãè¡æ¶²äžã®ççãã€ãªããŒã«ãŒãäžæããŠããé²è¡ããã®æ£è
ãæ²»çããINB03ãã¢ã«ããã€ããŒç
ã®æ²»çã®ããã®XPro1595ãéã¢ã«ã³ãŒã«æ§èèªèçã®æ£è
ãæ²»çããããã®LivNateããµã€ãã«ã€ã³æŸåºçå矀ããã³COVID-19ã®å䜵çã«å¯ŸããQuellorãªã©ããããŸããå瀟ã¯ãXencor, Inc.ãImmune Ventures, LLCããããããŒã°å€§åŠã INmune Bio, Inc. 㯠2015 幎ã«èšç«ããããããªãå·ãã«ã©ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã